Quarterly ResultAug 13, 2026, 04:14 PM
ProMIS Neurosciences Q2 Net Loss $(11.7M); Cash $53.4M
AI Summary
ProMIS Neurosciences reported a net loss of $(11.7) million for Q2 2026, an increase from $(10.1) million in Q2 2025. For the first six months of 2026, the net loss was $(20.0) million. The company significantly improved its cash position to $53.4 million as of June 30, 2026, up from $6.1 million at year-end 2025, primarily due to $70.1 million in net proceeds from a January 2026 private placement. The company expects existing cash to fund operations through 2027.
Key Highlights
- Net loss for Q2 2026 was $(11.7) million, compared to $(10.1) million in Q2 2025.
- Net loss for H1 2026 was $(20.0) million, up from $(17.5) million in H1 2025.
- Cash balance increased to $53.4 million at June 30, 2026, from $6.1 million at Dec 31, 2025.
- Received $70.1 million in net proceeds from a January 2026 PIPE financing.
- Shareholders' equity turned positive to $49.4 million from a $(1.3) million deficit.
- Research and development expenses rose to $16.5 million for H1 2026 from $14.2 million.
- Net cash used in operating activities was $(22.8) million for H1 2026.
- Existing cash and investments are expected to fund operations through 2027.
Price Impact
More from PMN